Tg Therapeutics (TGTX) Total Non-Current Liabilities (2010 - 2026)

Tg Therapeutics' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $944.9 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 126.47% year-over-year to $944.9 million in Q1 2026; TTM through Mar 2026 was $944.9 million, a 126.47% increase from a year earlier, with the FY2025 full-year figure at $413.1 million, up 17.52% from the prior year.
• Total Non-Current Liabilities rose to $944.9 million in Q1 2026 per TGTX's latest filing, from $413.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $944.9 million in Q1 2026 and bottomed at $134.7 million in Q4 2022.
• The 5-year median for Total Non-Current Liabilities is $390.8 million (2024), against an average of $372.0 million.
• Across the five-year window, Total Non-Current Liabilities retreated 5.19% in 2022 and surged 126.47% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $134.7 million in 2022, then increased by 25.22% to $168.7 million in 2023, then surged by 108.34% to $351.5 million in 2024, then grew by 17.52% to $413.1 million in 2025, then jumped by 128.72% to $944.9 million in 2026.
• Per Business Quant, the three latest TGTX Total Non-Current Liabilities figures stand at $944.9 million (Q1 2026), $413.1 million (Q4 2025), and $415.8 million (Q3 2025).